Bio Pharma Dive
OCTOBER 8, 2021
Initial study results for Relay's experimental treatment offer some support for the biotech's protein motion technology, but raise some questions, too.
Pharma Mirror
OCTOBER 4, 2021
By Kambiz Shekdar, Ph.D. Open source drug discovery was proposed in the past in connection with third-world diseases like tuberculosis and malaria, but it is in the context of first-world indications where it is needed most. Despite untold investment by numerous pharmaceutical companies, FDA-approved drugs that target critical brain functions and conditions like anxiety, depression, and sedation continue to present severe and unpredictable side effects, including suicidal ideation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
OCTOBER 5, 2021
SUMMARY: Americans spend twice as much per capita on drugs as residents of other wealthy nations, because ours is the only country that lets drugmakers set any price they want for their products. Seventy-nine percent of Americans think the price of prescription drugs is “unreasonable,” according to a 2019 Kaiser Family Foundation poll , and about 9 in 10 say they support the idea of the government negotiating prices.
Drug Patent Watch
OCTOBER 4, 2021
This is my talk from the 14th Annual Portfolio Planning and Partnership for Generic Conference. I discuss: Identifying generic entry opportunities at the earliest stages Discovering opportunities that avoid litigation…. The post Generic Portfolio Management, Partnering with Brands, and Staying Competitive appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
OCTOBER 4, 2021
Drugmaker initial public offerings could break records set just a year ago. But valuations and stock performance have slipped from historic highs.
Pharma Mirror
OCTOBER 2, 2021
“In a year when literally hundreds of our exhibitors have contributed to overcoming COVID, the greatest healthcare challenge of recent times, we are delighted to be welcoming back the pharma community. CPhI Worldwide is an essential conduit in helping pharma supply chains work, partners meet, empowering the industry with learning. But this year, more than ever, the event will also be a celebration of everything pharma has achieved.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
OCTOBER 8, 2021
The developer of a toolkit that promises to create a “digital twin” of individuals with chronic metabolic diseases like diabetes to help model the impact of lifestyle changes has secured $140 million in funding to develop the technology. US and India-based Twin Health says the Whole Body Digital Twin platform uses Internet of Things (IoT) sensors and self-reported data within an artificial intelligence-driven software platform to generate a virtual copy of a person’s unique met
Bio Pharma Dive
OCTOBER 6, 2021
Voyager Therapeutics recently scrapped much of its pipeline and replaced top executives. Now, a Pfizer deal on new technology gives investors hope.
Pharma Times
OCTOBER 8, 2021
A chemotherapy drug, NUC-7738, which is derived from a Himalayan fungus has been found to have 40 times greater potency in killing cancer cells than its original parent compound.
World of DTC Marketing
OCTOBER 6, 2021
SUMMARY: Via Axios – The antiviral pill that showed promising results against severe COVID-19 was initially developed at Emory University with $35 million of taxpayer grants. And while it costs $17.74 to produce, according to a report issued last week by drug pricing experts at the Harvard School of Public Health and King’s College Hospital in London.
pharmaphorum
OCTOBER 5, 2021
Digital data collection, utilisation of real-word data and patient-centric thinking will all contribute to the rapid development of a new healthcare landscape, says Debiopharm Innovation Fund’s Tanja Dowe. In recent years, we have seen thinking shift from focusing on a disease’s treatment to seriously considering the wider potential for its prevention, enabled by dramatic advances in data science and supported by a pressing need to reduce healthcare costs.
Bio Pharma Dive
OCTOBER 7, 2021
Founded by former Biogen executive Michael Ehlers and backed by Apple Tree Partners, Intergalactic aims to create non-viral gene therapies delivered via an advanced form of electroporation.
Pharma Mirror
OCTOBER 7, 2021
The history of medical writing began with the rise of the modern clinical trial. A medical writer can be your most pivotal ally in a clinical trial. While clinic directors, data managers, and investigators in the pharmaceutical industry are required for clinical trials, medical writers are the glue that holds clinical trials together. The increase in volume of clinical trials has already put a tremendous strain on journal editors and reviewers.
World of DTC Marketing
OCTOBER 2, 2021
SUMMARY: The health information on Facebook is a danger to anyone who reads it. Experiences from current patients do provide some context but too often contain lousy advice. Facebook should post a warning on every page that deals with health issues that informs people that their physician is still their best source of information. I joined some “private” healthcare condition pages on Facebook and was taken back by the amount of misinformation and bad advice.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Times
OCTOBER 6, 2021
UK-based Scancell Holdings has announced that its first subject has been dosed in its COVIDITY clinical trial in South Africa.
Bio Pharma Dive
OCTOBER 4, 2021
Initiation of the Phase 3 trial is an important milestone for the biotech after earlier setbacks, as well as for patients with the inherited muscle disease.
Pharma Mirror
OCTOBER 6, 2021
Limerick, Ireland: Irish SFI-funded research centre SSPC has announced a major collaboration with five of the world’s leading BioPharma companies that aims to reduce waste, maintain standards and minimise costs in pharmaceutical processes. The rising need for early diagnosis of chronic diseases, coupled with growing demand for drugs which work better and have fewer side effects, is largely responsible for the growth of the protein A resin market.
XTalks
OCTOBER 8, 2021
Medtronic has expanded a Class I recall of remote controllers used with the MiniMed 508 insulin pump or the MiniMed Paradigm family of insulin pumps over potential cybersecurity risks. The affected remote controller models are MMT-500 and MMT-503. The medtech giant has also expanded another Class I recall of the retainer rings on its 600 series insulin pumps.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharma Times
OCTOBER 4, 2021
MSD and Ridgeback Therapeutics announced that their investigational anti-viral medicine reduced the risk of hospitalisation and death by approximately 50% in non-hospitalised adult patients with mild-to-moderate COVID-19.
Bio Pharma Dive
OCTOBER 7, 2021
Researchers found evidence of a "chromosomal abnormality" in one patient treated with Allogene's CAR-T cell therapy, spurring the clinical hold and an investigation.
Pharma Mirror
OCTOBER 6, 2021
Abu Dhabi, UAE – Etihad Cargo, the cargo and logistics arm of Abu Dhabi’s Etihad AviationGroup, has expanded its pharma sector reach into Africa with the signing of a Service LegalAgreement (SLA) with Astral Aviation and Kenya Airways to provide reliable and cost-effective airfreight solutions across the continent.Operating a fleet of 14 freighters out of its Nairobi and Johannesburg hub, Astral Aviationservices a network of 15 African destinations, which Etihad Cargo will leverage for increased
pharmaphorum
OCTOBER 5, 2021
Since 2019, pharmaceutical companies have been speeding to integrate digital channels and processes into their marketing efforts and patient outreach, to prepare for the wave of digitisation in the healthcare industry. As part of these efforts, customer experience (CX) became a key focus area to ensure customer engagement and loyalty. Significant strides have been made by the industry when it comes to embedding forward-thinking practices into its strategic marketing goals with healthcare profess
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
OCTOBER 7, 2021
AstraZeneca has submitted an emergency approval to the US drug regulators for its COVID-19 antibody cocktail, which would be the first non-vaccine protection from the virus to be granted approval.
Bio Pharma Dive
OCTOBER 4, 2021
Tecartus, Gilead's second cell therapy on the market, is the first CAR-T treatment to be cleared for use in people older than 18 with ALL.
Pharma Mirror
OCTOBER 6, 2021
MENLO PARK, Calif., FOSTER CITY, Calif. and HANGZHOU, China, Edison Oncology Holding Corp. (‘Edison Oncology’), a company established to develop new therapies targeting the fight against cancer, and Apollomics Inc. (‘Apollomics’), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, reported that the first patient was dosed with EO1001 (APL-122) in a Phase I/IIa clinical trial in patients with adva
BioSpace
OCTOBER 5, 2021
Unlike most companies addressing the diseases associated with aging, Rejuvenate Bio tackles multiple cardiac, metabolic and renal issues at once.
pharmaphorum
OCTOBER 4, 2021
NHSX, the government agency tasked with digitally transforming NHS England, has granted funding to 14 projects in its first digital health award competition. The Digital Health Partnership Award opened for applications in July and is aimed at projects that can help NHS organisations in England support patients with long term conditions focusing on supporting people at home.
Bio Pharma Dive
OCTOBER 7, 2021
Neumora Therapeutics launched Thursday with a $100 million investment from Amgen and another $400 million from a long list of venture capital firms, including Arch, which is taking another shot at building a neuroscience company.
Pharma Times
OCTOBER 6, 2021
The UK’s first ‘asthma bus’ is set to begin its journey around the country, aiming to offer crucial support to pressured NHS respiratory services, as asthma sufferers have admitted to delaying care during the pandemic to avoid the risk of catching COVID-19.
Outsourcing Pharma
OCTOBER 5, 2021
A representative from the school explains how tools like artificial intelligence and natural language processing can help elevate personalized medicine.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Expert insights. Personalized for you.
359 
Let's personalize your content